This enduring activity captures the key elements from the virtual live which aims to improve oncologists’, including lung cancer specialists, community clinicians, and APPs, knowledge and competence in applying the latest ADC data and clinical recommendations to optimize outcomes for patients with NSCLC. As a result of this educational curriculum, learners will be better able to: 1. Interpret the latest clinical trial data for approved and emerging antibody-drug conjugates (ADCs) in NSCLC; 2. Recognize biomarker-driven strategies to guide treatment management in patients with NSCLC; and, 3. Apply evidence-based strategies for the individualized management of patients with NSCLC receiving ADC therapy. Learners will have access to downloadable materials.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 27 Trinity Place, Suite 185
Pricing
99% of listed courses are free
156 of 157 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Oncology
- Nephrology
- Neurocritical Care
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Microlearning
- includes Online course / module
- Credit · Up to 0.5 credits
- MOC · Up to 0.5 points
- Commercial Support
-
ReleasedDec 16, 2025
-
Last day to claim creditDec 16, 2026 2 months left
-
Answers in CME Inc. (AiCME) What s Now and What s Next for ADCs in NSCLC? Integrating HER2- and TROP2-Targeted Therapies Into the Evolving Treatment Landscape
-
Answers in CME Inc. (AiCME) Navigating ADC Therapy in Lung Cancer: An APP Guide to Selection, Safety, and Care Coordination
-
Answers in CME Inc. (AiCME) New Frontiers in Small Cell Lung Cancer: Getting Ready for the Emergence of B7-H3 Directed ADCs
-
Physicians’ Education Resource Optimizing NSCLC Readiness in the Era of TROP2-Targeted ADCs: Frontline Combinations, CNS Disease, and Toxicity Differentiation
-
Plexus Communications +1 New Horizons in NSCLC: The Role of ADCs in Enhancing Personalized Care in HER2-Altered Disease 2026
-
Clinical Care Options, LLC (dba Decera Clinical Education) HER2- and TROP2-Directed ADCs in NSCLC: Patient Selection, Treatment Sequencing, and Toxicity Management in a Rapidly Evolving Landscape
